Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.

Annals of hematology - 1 May 2002

Pfitzner T, Reiser M, Barth S, Borchmann P, Schulz H, Schinköthe T, Oberhäuser F, Wessels J, Tur M, Diehl V, Engert A

Abstract excerpt

New therapeutic approaches for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) can induce remarkable responses. Molecular remissions have been observed occasionally after high-dose chemotherapy. Thus, new improved techniques to monitor residual tumor cells on a molecular basis in CLL are warranted. For this purpose, a real-time quantitative allele-specific oligonucleotide polymerase chain reaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Computer Systems

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm, Residual

Share to Neoplastic Cells, Circulating

Share to Rituximab

Share to Vidarabine

Source

Identifiers

PMID: 12029535
DOI: 10.1007/s00277-002-0449-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.PMID 12029535Read ↗

PCR for monitoring of minimal residual disease in hematologic malignancy.Semantic proximity Read ↗

Measurable residual disease in chronic myeloid leukemiaSemantic proximity Read ↗

A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsSemantic proximity Read ↗

[Evaluation of minimal residual disease using allele (mutation) -specific PCR].Semantic proximity Read ↗

Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.Semantic proximity Read ↗

Remission Assessment by Circulating Tumor DNA in Large B-Cell LymphomaSemantic proximity Read ↗

Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‐color flow cytometry protocol in routine hematological practiceSemantic proximity Read ↗

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Semantic proximity Read ↗

Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction.Semantic proximity Read ↗

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?Semantic proximity Read ↗

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.